Marico's Q1 FY26 results, resurfacing an August move: revenue rose 23%, stake in Plix maker Satiya Nutraceuticals lifted to 60%
Resurfacing an August 2025 disclosure, Marico reported Q1 FY26 consolidated net profit of Rs 513 crore, up 8.2% year on year, as revenue from operations rose 23.3% to Rs 3,259 crore. India revenue grew 27.2%, while international revenue increased 12.9%. The company also raised its fully diluted stake in Plix maker Satiya Nutraceuticals to 60%.
What happened
Marico posted Q1 FY26 profit growth of 8.2% and revenue growth of 23.3%, led by 27.2% India revenue growth. It raised its stake in Plix maker Satiya
Key facts
- Q1 FY26 consolidated net profit: Rs 513 crore, up 8.2% YoY from Rs 474 crore
- Revenue from operations: Rs 3,259 crore, up 23.31% YoY from Rs 2,643 crore
- Total income: Rs 3,315 crore, including Rs 56 crore other income
- India revenue: Rs 2,495 crore, up 27.17% YoY from Rs 1,962 crore
- International revenue: Rs 764 crore, up 12.91% YoY from Rs 681 crore
- India segment PBT: Rs 469 crore
- International segment PBT: Rs 213 crore
- Total expenses: Rs 2,659 crore, up from Rs 2,075 crore
- Marico increased its Satiya Nutraceuticals stake to 60% on a fully diluted basis
Why this matters
By lifting its stake in Plix maker Satiya Nutraceuticals to 60%, Marico is deepening control of a high-growth nutrition platform and expanding beyond its core FMCG portfolio.
What to watch
- Quarterly volume growth versus price-led growth in India.
- Gross-margin movement and management commentary on copra, edible oil, crude derivatives and packaging costs.
- Plix revenue growth, distribution expansion, EBITDA trajectory and any change in minority buyout plans.
- Advertising-and-promotion spend as a percentage of sales.
- International revenue recovery, particularly in Bangladesh, MENA and South Africa.
- Rural demand trends, modern-trade growth and premium-category contribution.
- Whether profit growth closes the gap with revenue growth in the next two quarters.
- Expand Plix into Marico's general trade, modern trade and pharmacy distribution network while preserving its digital-native positioning.
- Increase cross-selling and premium portfolio launches across nutrition, healthy foods, personal care and convenience-led wellness products.
- Use strong India growth to raise advertising and promotional investment, especially in premium and urban categories.
- Pursue selective bolt-on investments in health, nutrition and digital-first consumer brands rather than relying solely on core edible-oil and hair-care categories.
- Calibrate pricing and pack-size actions to protect gross margins if commodity costs rise.